Clinic outcome of ticagrelor in treatment of patients with acute ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention
10.3760/cma.j.issn.1008-1372.2014.09.016
- VernacularTitle:替格瑞洛在急性ST段抬高型心肌梗死急诊PCI中应用的疗效观察
- Author:
Ruiwei GUO
;
Lixia YANG
;
Feng QI
;
Changzheng CHEN
- Publication Type:Journal Article
- Keywords:
Platelet aggregation inhibitors/therapeutic use;
Myocardial infarction/therapy;
Acute disease;
Angioplasty,transluminal,percutaneous coronary;
Emergency treatment;
Treatment outcome
- From:
Journal of Chinese Physician
2014;16(9):1213-1215
- CountryChina
- Language:Chinese
-
Abstract:
Objectives To investigate clinic outcome of ticagrelor in treatment of patients with acute ST-segment elevation my ocardial infarction receiving primary percutaneous coronary intervention.Methods Sixty-two consecutive patients with ST segment elevation myocardial infarction (STEMI) receiving primary percutaneous coronary intervention (PCI) were included in this study.The clinic characteristics,thrombolysis in myocardial infarction (TIMI) refuse after PCI,clinical outcomes after 30 d of patients were compared between patients who were treated with ticagrelor (group A 30 cases) and clopidogrel (group B 32 cases).Results There was no difference in the age,proportion of women,hypertension,and diabetics (P ＞ 0.05).TIMI 3 refuse after PCI were significantly higher in group A than group B (96.7％ vs 87.5％,P ＜ 0.05).The 30 d re-angina pectoris was lower in group A than group B (3.3％ vs 12.5％,P ＜0.05).However,tiny bleeding of group A was higher than group B (13.3％ vs 3.1％,P ＜0.05).Conclusions Ticagrelortreatment can improve the prognosis of STEMI receiving primary PCI,but increase the risk of bleeding.
